VCYT stock news today

Veracyte, Inc. Posts Third Quarter 2026 Earnings

Veracyte, Inc. released its quarterly numbers for the three months ending in 2026's third quarter. The filing covers the diagnostics company's performance for that period.

Veracyte Discusses Third-Quarter 2026 Results on Conference Call

Veracyte hosted a call covering its financial performance for the third quarter of 2026, and a written record of the discussion is available.

Veracyte announces $100M share buyback plan

Veracyte said it will repurchase up to $100 million of its own stock. A buyback can reduce the number of shares outstanding.

Veracyte trims FY2026 sales outlook to $590M-$593M

Veracyte narrowed its full-year 2026 revenue forecast to a range of $590 million to $593 million. The prior range was $590 million to $596 million, and analysts had expected $593.894 million.

Veracyte posts Q3 adjusted profit of $0.51 per share, topping $0.41 consensus

Veracyte's third-quarter adjusted earnings came in at $0.51 per share, ahead of the $0.41 analysts expected. Revenue of $151.754 million also exceeded the $147.439 million consensus.

Form 4 reports shares bought or sold by company insiders such as officers, directors or large holders.

Veracyte Releases New Data on Decipher Prostate Genomic Classifier

Veracyte announced new data for its Decipher Prostate Genomic Classifier. The data relates to the company's prostate cancer testing product.

Veracyte says Decipher Prostate test predicted abiraterone benefit in STAMPEDE trial

Veracyte reported that a Phase III STAMPEDE analysis showed its Decipher Prostate test can identify which patients gain from adding abiraterone to ADT. The study found a larger five-year gain for high-scoring patients than for those with lower scores.

Veracyte wins coverage for Prosigna breast recurrence test after MolDX review

Veracyte said its Prosigna test, which gauges the risk of breast cancer returning, has been granted coverage following a technical assessment. The decision applies to the MolDX program run by Palmetto GBA.

Veracyte buys Convergent Genomics for $150M plus up to $30M in milestones

Veracyte is acquiring Convergent Genomics in a deal valued at $150 million, with potential additional milestone payments of up to $30 million. The acquisition adds Convergent Genomics' business to Veracyte.

UBS keeps Buy rating on Veracyte, lifts target to $65

UBS reaffirmed its Buy rating on Veracyte and increased its price target to $65. The move reflects the analyst's updated view on the company.

What is the latest news on VCYT?

Nov 4, 2026: Veracyte, Inc. Posts Third Quarter 2026 Earnings (Fiscal.ai) · Nov 4, 2026: Veracyte Discusses Third-Quarter 2026 Results on Conference Call (Benzinga) · Nov 4, 2026: Veracyte announces $100M share buyback plan (Benzinga)

What has VCYT filed with the SEC recently?

Oct 28, 2026: Veracyte, Inc. filed an insider trading report (Form 4)